Literature DB >> 3258663

Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease.

K Y Ngo1, V T Glotz, J A Koziol, D C Lynch, J Gitschier, P Ranieri, N Ciavarella, Z M Ruggeri, T S Zimmerman.   

Abstract

Severe von Willebrand disease is characterized by undetectable or trace quantities of von Willebrand factor in plasma and tissue stores. We have studied the genomic DNA of 10 affected individuals from six families with this disorder using probes from the 5' and 3' ends of the vWF cDNA and with a probe extending from the 5' end into the central region. Southern blots of restriction endonuclease digests and gene dosage analysis measurements carried out with quantitative slot blots of undigested genomic DNA separated these patients into three groups. The first group consisted of a family with complete homozygous deletions of the vWF gene in the four probands. Gene dosage analysis was consistent with heterozygous deletions in both of the asymptomatic parents and four asymptomatic siblings of this kindred (P less than 0.01). The second group was comprised of a family in which there was a complete heterozygous deletion of the vWF gene in the proband and one asymptomatic parent, suggesting that a different type of genetic abnormality was inherited from the other parent. Thus, the patient appeared to be doubly heterozygous for interacting genetic abnormalities affecting vWF expression. In the third group, no gene deletions could be detected. Alloantibodies developed only in the kindred with homozygous deletions. These techniques should prove useful in identifying carriers of severe von Willebrand disease and also in defining patients predictably at risk of developing alloantibodies to vWF.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258663      PMCID: PMC280077          DOI: 10.1073/pnas.85.8.2753

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  In vivo dissociation of factor VII (AHF) activity and factor VII-related antigen in von Willebrand's disease.

Authors:  E C Lian; D Deykin
Journal:  Am J Hematol       Date:  1976       Impact factor: 10.047

2.  Determination of the base composition of deoxyribonucleic acid from its thermal denaturation temperature.

Authors:  J MARMUR; P DOTY
Journal:  J Mol Biol       Date:  1962-07       Impact factor: 5.469

3.  A general method for isolation of high molecular weight DNA from eukaryotes.

Authors:  N Blin; D W Stafford
Journal:  Nucleic Acids Res       Date:  1976-09       Impact factor: 16.971

4.  Kinetics of renaturation of DNA.

Authors:  J G Wetmur; N Davidson
Journal:  J Mol Biol       Date:  1968-02-14       Impact factor: 5.469

5.  A simple sensitive prenatal test for hydrops fetalis caused by alpha-thalassaemia.

Authors:  E M Rubin; Y W Kan
Journal:  Lancet       Date:  1985-01-12       Impact factor: 79.321

6.  Determination of nucleic acid sequence homologies and relative concentrations by a dot hybridization procedure.

Authors:  F C Kafatos; C W Jones; A Efstratiadis
Journal:  Nucleic Acids Res       Date:  1979-11-24       Impact factor: 16.971

7.  Polymorphism of DNA sequence adjacent to human beta-globin structural gene: relationship to sickle mutation.

Authors:  Y W Kan; A M Dozy
Journal:  Proc Natl Acad Sci U S A       Date:  1978-11       Impact factor: 11.205

8.  Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization.

Authors:  D Ginsburg; R I Handin; D T Bonthron; T A Donlon; G A Bruns; S A Latt; S H Orkin
Journal:  Science       Date:  1985-06-21       Impact factor: 47.728

9.  Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method.

Authors:  D C Lynch; T S Zimmerman; C J Collins; M Brown; M J Morin; E H Ling; D M Livingston
Journal:  Cell       Date:  1985-05       Impact factor: 41.582

10.  Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene.

Authors:  C L Verweij; C J de Vries; B Distel; A J van Zonneveld; A G van Kessel; J A van Mourik; H Pannekoek
Journal:  Nucleic Acids Res       Date:  1985-07-11       Impact factor: 16.971

View more
  17 in total

1.  Germ-line mosaicism for a valine-to-methionine substitution at residue 553 in the glycoprotein Ib-binding domain of von Willebrand factor, causing type IIB von Willebrand disease.

Authors:  E W Murray; A R Giles; D Lillicrap
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

2.  Translational medicine advances in von Willebrand disease.

Authors:  D Lillicrap
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

Review 3.  von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.

Authors:  Paula D James; David Lillicrap
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

4.  A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide.

Authors:  W F Bahou; D Ginsburg; R Sikkink; R Litwiller; D N Fass
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

5.  Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA.

Authors:  D Ginsburg; B A Konkle; J C Gill; R R Montgomery; P L Bockenstedt; T A Johnson; A Y Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

6.  Severe von Willebrand disease due to a defect at the level of von Willebrand factor mRNA expression: detection by exonic PCR-restriction fragment length polymorphism analysis.

Authors:  W C Nichols; S E Lyons; J S Harrison; R L Cody; D Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

7.  Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.

Authors:  E Berntorp; B Fuchs; M Makris; R Montgomery; V Flood; J S O'Donnell; A B Federici; D Lillicrap; P James; U Budde; M Morfini; P Petrini; S Austin; C Kannicht; V Jiménez-Yuste; C Lee
Journal:  Haemophilia       Date:  2013-03       Impact factor: 4.287

8.  Inheritance and prevalence of von Willebrand's disease severe form in a Brazilian population.

Authors:  R R Fischer; C Lerner; E Bandinelli; A S Fonseca; I Roisenberg
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

9.  Genetic and blood coagulation characterization of "Swedish" families with von Willebrand's disease types I and III: new aspects of heredity.

Authors:  M Anvret; M Blombäck; M Lindstedt; E Söderlind; M Tapper-Persson; A C Thelander
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

10.  The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles.

Authors:  M Bowman; A Tuttle; C Notley; C Brown; S Tinlin; M Deforest; J Leggo; V S Blanchette; D Lillicrap; P James
Journal:  J Thromb Haemost       Date:  2013-03       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.